CA2893883A1 - Delphinidin for combating melanoma cells - Google Patents

Delphinidin for combating melanoma cells Download PDF

Info

Publication number
CA2893883A1
CA2893883A1 CA2893883A CA2893883A CA2893883A1 CA 2893883 A1 CA2893883 A1 CA 2893883A1 CA 2893883 A CA2893883 A CA 2893883A CA 2893883 A CA2893883 A CA 2893883A CA 2893883 A1 CA2893883 A1 CA 2893883A1
Authority
CA
Canada
Prior art keywords
delphinidin
composition
cells
sbe
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2893883A
Other languages
English (en)
French (fr)
Inventor
Norbert Roewer
Jens Broscheit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapiotec GmbH
Original Assignee
Sapiotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec GmbH filed Critical Sapiotec GmbH
Publication of CA2893883A1 publication Critical patent/CA2893883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
CA2893883A 2012-12-11 2013-11-28 Delphinidin for combating melanoma cells Abandoned CA2893883A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012222777.6 2012-12-11
DE102012222777 2012-12-11
EP13150909 2013-01-11
EP13150909.3 2013-01-11
PCT/EP2013/074991 WO2014090586A1 (de) 2012-12-11 2013-11-28 Delphinidin zur bekämpfung von melanomzellen

Publications (1)

Publication Number Publication Date
CA2893883A1 true CA2893883A1 (en) 2014-06-19

Family

ID=49679524

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2893883A Abandoned CA2893883A1 (en) 2012-12-11 2013-11-28 Delphinidin for combating melanoma cells
CA2893881A Expired - Fee Related CA2893881C (en) 2012-12-11 2013-11-28 Delphinidin for combating melanoma cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2893881A Expired - Fee Related CA2893881C (en) 2012-12-11 2013-11-28 Delphinidin for combating melanoma cells

Country Status (8)

Country Link
US (2) US9511047B2 (OSRAM)
EP (2) EP2931286B1 (OSRAM)
JP (2) JP6234475B2 (OSRAM)
KR (2) KR102164174B1 (OSRAM)
CN (2) CN104918622A (OSRAM)
CA (2) CA2893883A1 (OSRAM)
HK (1) HK1215392A1 (OSRAM)
WO (2) WO2014090583A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
KR102164174B1 (ko) * 2012-12-11 2020-10-12 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946228A (ja) 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8907008D0 (en) 1989-03-28 1989-05-10 Inverni Della Beffa Spa Intermediates useful for the synthesis for delphinidin chloride
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
EP1666591B1 (en) * 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
GB2307176A (en) 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
JP4101346B2 (ja) 1998-02-18 2008-06-18 ダイセル化学工業株式会社 酸化触媒系及びそれを用いた酸化方法
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
US6576261B1 (en) 1999-08-11 2003-06-10 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
WO2001030391A2 (en) 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
DE60114860T2 (de) 2000-09-12 2006-05-24 Meiji Seika Kaisha Ltd. Verfahren zur Herstellung von gereinigtem Anthocyanin und kristallinem Anthocyanin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003171274A (ja) 2001-12-07 2003-06-17 Tomihiko Higuchi 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
WO2003063824A2 (en) 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
JPWO2005067905A1 (ja) 2004-01-14 2007-12-27 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
CN1317961C (zh) 2004-03-25 2007-05-30 吴朝琴 冻干草莓加工工艺
CN100342026C (zh) * 2004-05-13 2007-10-10 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
DE102005017775A1 (de) 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
KR100733913B1 (ko) * 2005-08-30 2007-07-02 한국화학연구원 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR100756656B1 (ko) 2006-12-12 2007-09-10 한국화학연구원 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품
KR100880876B1 (ko) 2007-04-11 2009-01-30 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
JP5574600B2 (ja) 2007-12-17 2014-08-20 日本製薬工業株式会社 吸収性骨疾患の予防・治療剤
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20120083460A1 (en) 2009-03-25 2012-04-05 San Ei Gen F.F.I., Inc. Readily water-soluble isoquercitrin composition
EP2437770A4 (en) 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
KR101625882B1 (ko) 2009-10-21 2016-05-31 마뀌 뉴 라이프 에스. 에이. 안토시아니딘을 포함하는 조성물 및 이용방법
EP2345427A1 (de) 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
CN106036793B (zh) 2010-03-13 2020-11-06 伊斯顿庞德实验室有限公司 结合脂肪的组合物
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
AU2010366535A1 (en) 2010-12-31 2013-07-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
DK2484350T3 (en) 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
JP6193970B2 (ja) 2012-03-30 2017-09-06 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対するデルフィニジンの使用
CA2869056C (en) 2012-03-30 2020-02-25 Sapiotec Gmbh Anthocyanidin complex
JP2015534970A (ja) 2012-10-17 2015-12-07 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 多発性骨髄腫の治療のためのアントシアニジン複合体
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
KR102164174B1 (ko) * 2012-12-11 2020-10-12 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP2913366A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex

Also Published As

Publication number Publication date
CA2893881C (en) 2020-09-22
HK1216229A1 (zh) 2016-10-28
JP2016502984A (ja) 2016-02-01
WO2014090586A1 (de) 2014-06-19
CN104918622A (zh) 2015-09-16
JP6234475B2 (ja) 2017-11-22
HK1215392A1 (zh) 2016-08-26
EP2931286A1 (de) 2015-10-21
JP2016502985A (ja) 2016-02-01
US9949947B2 (en) 2018-04-24
KR20150107741A (ko) 2015-09-23
EP2931286B1 (de) 2017-10-04
WO2014090583A1 (de) 2014-06-19
KR102164174B1 (ko) 2020-10-12
US20150320719A1 (en) 2015-11-12
CN104936601A (zh) 2015-09-23
EP2931287B1 (de) 2017-10-04
EP2931287A1 (de) 2015-10-21
US9511047B2 (en) 2016-12-06
JP6234476B2 (ja) 2017-11-22
KR20150107742A (ko) 2015-09-23
CA2893881A1 (en) 2014-06-19
US20150328336A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
Zhang et al. Targeting ferroptosis by polydopamine nanoparticles protects heart against ischemia/reperfusion injury
Gigliotti et al. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors
Xiao et al. Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy via excessive autophagy
Spruß et al. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma
Yu et al. Aggregation‐induced emission photosensitizer‐engineered anticancer nanomedicine for synergistic chemo/chemodynamic/photodynamic therapy
Wang et al. Aggregation-induced emission photosensitizer synergizes photodynamic therapy and the inhibition of the NF-κB signaling pathway to overcome hypoxia in breast cancer
CA2893881C (en) Delphinidin for combating melanoma cells
Huang et al. Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis
CN101537185A (zh) 一种肿瘤细胞主动靶向载药系统及其制备方法和应用
Gao et al. Application of capsaicin and calcium phosphate-loaded MOF system for tumor therapy involving calcium overload
JP2008297549A (ja) 金属−多糖複合体の組成および合成
CN104780925A (zh) 用于治疗多发性骨髓瘤的花青素络合物
Zhao et al. Simultaneous inhibition of heat shock proteins and autophagy enhances radiofrequency ablation of hepatocellular carcinoma
Li et al. Erythrocyte Membrane-Camouflaged Xanthohumol Nanoparticles Mitigate Doxorubicin-Induced Cardiotoxicity by Inhibiting Ferroptosis
RU2271813C1 (ru) Способ коррекции морфологического состояния печени опухоленосителя
HK1216229B (en) Delphinidin for combating melanoma cells
CN115531554B (zh) 合成致死纳米药物组合载体及其在制备治疗gbm靶向药物上的应用
Li et al. A mitochondria-targeted nanomedicine for myocardial ischemia/reperfusion injury with synergistic antioxidant and anti-inflammatory properties
KR20240130500A (ko) 베라파밀을 포함하는 대사증후군 치료용 경피약물전달 패치 조성물
Luo et al. Treatment of Bleomycin-induced Pulmonary Fibrosis by Intratracheal Instillation Administration of Ellagic Acid-Loaded Chitosan Nanoparticles
CN120661678A (zh) 一种基于天然产物线粒体靶向自组装protac纳米材料及其制备方法与应用
Maestroni et al. Association of melatonin with nuclear grade and estrogen receptor status in human breast cancer
Shin et al. Anti-cancer Activities of Anthocyanins of Vitis Coignetiae Pulliat in Human Hepatocelluar Carcinoma Cells
JP2018002663A (ja) 抗アレルギー剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181105

FZDE Discontinued

Effective date: 20210305